A phase II trial of lenvatinib in patients with metastatic colorectal cancer after standard chemotherapy (NCCH1503,Lemon trial)
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000023446
- Lead Sponsor
- ational Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
1)Active double cancer; synchronous or metachronous within 5years. Patients with carcinoma in situ are eligible 2)Infections requiring systemic therapy 3)Fever of >=38 degrees Celsius at the time of registration 4)Grade >=2 adverse reactions caused by prior therapy except any grade of alopecia and grade 2 peripheral neurotoxicity 5)Pregnant or breast-feeding women,or women suspected of being pregnant 6)Mental disease interfering taking part in the trial 7)Taking continuous systemic steroids and/or other immunosuppressive drugs(orally or intravenously) 8)HIV antibody positive 9)Interstitial pneumonia and/or pulmonary fibrosis and/or severe pulmonary emphysema diagnosed by chest CT imaging 10)History of any of the followings; unstable angina and transient ischemic attacks within 6 months before registration, or heart attack,pulmonary embolism,deep vein thrombosis,brain bleeding,cerebral infarction and arterial thromboembolism
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease control rate
- Secondary Outcome Measures
Name Time Method Adverse events Overall response rate Progression-free survival Overall survival